Back to top

Matt Larew Reiterates Hold on CareDx as Favorable MolDX Coverage Decision Removes Key Reimbursement Overhang but Valuation Now Seen as Fair

William Blair analyst Matt Larew has maintained their neutral stance on CDNA stock, giving a Hold rating today. Matt Larew has given his Hold ratin...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

CareDx, Inc. (CDNA)